Compare · CLPT vs MMM
CLPT vs MMM
Side-by-side comparison of ClearPoint Neuro Inc. (CLPT) and 3M Company (MMM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLPT and MMM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MMM is the larger of the two at $92.51B, about 178.8x CLPT ($517.4M).
- Over the past year, CLPT is up 59.6% and MMM is up 14.5% - CLPT leads by 45.0 points.
- MMM has been more active in the news (5 items in the past 4 weeks vs 3 for CLPT).
- MMM has more recent analyst coverage (25 ratings vs 5 for CLPT).
- Company
- ClearPoint Neuro Inc.
- 3M Company
- Price
- $17.00+12.10%
- $179.38+0.22%
- Market cap
- $517.4M
- $92.51B
- 1M return
- +16.17%
- +0.67%
- 1Y return
- +59.58%
- +14.53%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 5
- Recent ratings
- 5
- 25
ClearPoint Neuro Inc.
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to perform minimally invasive surgical procedures in the heart. It has license and collaboration agreements with The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Microsystems, LLC, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Irvine, California.
3M Company
3M Company develops, manufactures, and markets various products worldwide. It operates through four business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment offers personal safety products, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules to industrial, electrical, and safety markets. The Transportation and Electronics provides electronics, such as display materials and systems, electronic materials solutions; automotive and aerospace, and commercial solutions; advanced materials; and transportation safety products to transportation and electronic original equipment manufacturer customers. The Health Care segment offers medical and surgical supplies, skin health and infection prevention products, oral care, separation and purification sciences, health information systems, drug delivery systems, and food safety products to healthcare industry. The Consumer segment provides home improvement, home care, and consumer health care products, as well as stationery and office supplies to various consumers. This segment is also involved in the retail auto care business. It offers its products through various e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers, as well as directly to users. 3M Company has a strategic collaboration with Merry Maids in residential cleaning sector; and collaborations with The Infectious Disease Research Institute and Duke Human Vaccine Institute to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2. The company was founded in 1902 and is headquartered in St. Paul, Minnesota.
Latest CLPT
- SEC Form 10-Q filed by ClearPoint Neuro Inc.
- ClearPoint Neuro Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- ClearPoint Neuro Reports Second Quarter 2026 Results
- ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel
- ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026
- Director Richards Timothy T. was granted 222 shares, increasing direct ownership by 0.25% to 87,544 units (SEC Form 4)
- Director Fletcher R John was granted 662 shares, increasing direct ownership by 0.51% to 131,011 units (SEC Form 4)
- Chief Business Officer Stigall L. Jeremy was granted 1,781 shares, increasing direct ownership by 2% to 110,263 units (SEC Form 4)
- Chief Financial Officer D'Alessandro Danilo was granted 1,085 shares, increasing direct ownership by 1% to 103,769 units (SEC Form 4)
- CEO and President Burnett Joseph was granted 1,361 shares, increasing direct ownership by 1% to 118,203 units (SEC Form 4)
Latest MMM
- 3M Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation
- SEC Form 3 filed by new insider George Bobby K
- SEC Form 3 filed by new insider Cunningham Jennifer A.
- 3M Board Declares Quarterly Dividend
- Group President Chavez Rodriguez Beatriz Karina sold $663,430 worth of shares (3,635 units at $182.51), decreasing direct ownership by 21% to 14,035 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by 3M Company
- Sr Vice President & CAO Reinseth Theresa E sold $156,544 worth of shares (924 units at $169.42), decreasing direct ownership by 26% to 2,615 units (SEC Form 4)
- Executive Vice President Banovetz John Patrick exercised 7,880 shares at a strike of $154.69 and sold $1,343,067 worth of shares (7,880 units at $170.44) (SEC Form 4)
- EVP, Chief Legal Off & Secret Rhodes Kevin H exercised 7,669 shares at a strike of $154.69 and sold $1,312,933 worth of shares (7,669 units at $171.20) (SEC Form 4)
- Group President Goralski Christian T Jr exercised 4,902 shares at a strike of $154.69 and sold $835,577 worth of shares (4,902 units at $170.46), decreasing direct ownership by 0.00% to 6,971 units (SEC Form 4)